A
AllRock Bio
Therapies for rare cardiopulmonary and fibrotic diseases
About AllRock Bio
AllRock Bio is a clinical-stage biotechnology company focused on developing and commercializing therapies for rare cardiopulmonary diseases like pulmonary hypertension and other fibrotic conditions. The company was founded in April 2024 by Catherine Pearce, DHSc, MBA, and Justin Thompson, MS. The firm's business model is centered on identifying and advancing promising drug candidates through efficient clinical trials to address unmet medical needs.
Read full description
CEO and Founder Catherine Pearce has over 25 years of experience in the biotech industry, with a track record of leading drug development programs and building successful companies. Before AllRock, she co-founded CinRx Pharma and was instrumental in the growth of its portfolio company, CinCor Pharma, which was acquired by AstraZeneca for up to $1.8 billion in 2023. Co-founder Justin Thompson also has over 20 years of experience in life sciences business development and venture capital, and played a key role alongside Dr. Pearce at CinCor Pharma.
AllRock Bio's lead program is ROC-101, an orally administered pan-ROCK inhibitor being investigated for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). ROC-101 aims to provide anti-proliferative, anti-inflammatory, and anti-fibrotic effects, potentially modifying disease progression rather than just managing symptoms. By inhibiting both ROCK1 and ROCK2 isoforms, the drug is intended to promote vasodilation, reduce vascular remodeling, and improve endothelial function. The company raised a Series A funding round in 2024 to advance the development of this therapeutic.
At a glance
- Status
- Operational
- Founded
- 2024
- Headquarters
- Natick, United States
- Employees
- 20
- Open positions
- None listed
- Dealroom signal
- 88.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Inflammatory Diseases, Chronic Disease, Pulmonary, Disease, Biotech and Pharma, Woman Founder, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Sep 2025 | $50M | $200M | Versant Ventures · Westlake Village BioPartners | ↗ |
Growth signals
Latest recorded traffic for AllRock Bio is 1.6K monthly website visits, up 1677.8% over the last three months. AllRock Bio's team grew 300% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Versant Ventures
Westlake Village BioPartners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about AllRock Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See AllRock Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.